CDH6 and neoplasm: Cell-cell adhesion molecules are emerging as a new class of TAAs for bispecific ADCs (Figure 3), and those targeting CDH3 x CDH17 (Synan et al., 2025), CDH6 x FRα (folate receptor alpha) (Zhang Y et al., 2025), CDH17 x CLDN18.2 (Wang W. V. et al., 2025) and CLDN3 x EpCAM (epithelial cell adhesion molecule) (Luo M. et al., 2025) have been shown to have anti-tumor effects on colorectal cancers, ovarian/kidney cancers, gastrointestinal cancers and solid tumors, respectively, in preclinical studies.